Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Aug;96(2):1026–1034. doi: 10.1172/JCI118088

Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.

S Scala 1, A Budillon 1, Z Zhan 1, Y S Cho-Chung 1, J Jefferson 1, M Tsokos 1, S E Bates 1
PMCID: PMC286382  PMID: 7543490

Abstract

8-Cl-cAMP, a site-selective analogue of cAMP, decreased mdr-1 expression in multidrug-resistant human breast cancer cells. A sixfold reduction of mdr-1 mRNA expression by 8-Cl-cAMP began within 8 h of treatment and was associated with a decrease in the synthesis of P-glycoprotein and with an increase in vinblastine accumulation. A reduction in mdr-1 expression after 8-Cl-cAMP treatment was also observed in multidrug-resistant human ovarian cancer cell lines. 8-Cl-cAMP is known to change the ratio between the two regulatory subunits, RI and RII, of protein kinase A (PKA). We observed that RI alpha decreased within 24 h of 8-Cl-cAMP treatment, that RII beta increased after as few as 3 h of treatment, and that PKA catalytic activity remained unchanged during 48 h of 8-Cl-cAMP treatment. The results are consistent with the hypothesis that mdr-1 expression is regulated in part by changes in PKA isoenzyme levels. Although 8-Cl-cAMP has been used to differentiate cells in other model systems, the only differentiating effect that could be detected after 8-Cl-cAMP treatment in the MCF-7TH cells was an increase in cytokeratin expression. Evidence that the reduction of mdr-1 mRNA occurred at the level of gene transcription was obtained by measuring chloramphenicol acetyltransferase (CAT) mRNA in MCF-7TH cells transfected with an mdr-1 promoter-CAT construct prior to 8-Cl-cAMP treatment. Thus, 8-Cl-cAMP is able to downregulate mdr-1 expression and suggests a new approach to reversal of drug resistance in human breast cancer.

Full text

PDF
1026

Images in this article

1028Image
on p.1028
1028Image
on p.1028
1029Image
on p.1029
1030Image
on p.1030
1031Image
on p.1031
1031Image
on p.1031
1031Image
on p.1031
1032Image
on p.1032

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham I., Chin K. V., Gottesman M. M., Mayo J. K., Sampson K. E. Transfection of a mutant regulatory subunit gene of cAMP-dependent protein kinase causes increased drug sensitivity and decreased expression of P-glycoprotein. Exp Cell Res. 1990 Jul;189(1):133–141. doi: 10.1016/0014-4827(90)90265-c. [DOI] [PubMed] [Google Scholar]
  2. Ally S., Tortora G., Clair T., Grieco D., Merlo G., Katsaros D., Ogreid D., Døskeland S. O., Jahnsen T., Cho-Chung Y. S. Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6319–6322. doi: 10.1073/pnas.85.17.6319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baral E., Auer G. In vitro effect of doxorubicin on non-proliferating and proliferating epithelial cells. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):963–965. doi: 10.1016/0360-3016(90)90019-g. [DOI] [PubMed] [Google Scholar]
  4. Bates S. E., Meadows B., Goldspiel B. R., Denicoff A., Le T. B., Tucker E., Steinberg S. M., Elwood L. J. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother Pharmacol. 1995;35(6):457–463. doi: 10.1007/BF00686829. [DOI] [PubMed] [Google Scholar]
  5. Bates S. E., Mickley L. A., Chen Y. N., Richert N., Rudick J., Biedler J. L., Fojo A. T. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol Cell Biol. 1989 Oct;9(10):4337–4344. doi: 10.1128/mcb.9.10.4337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burt R. K., Thorgeirsson S. S. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst. 1988 Nov 2;80(17):1383–1386. doi: 10.1093/jnci/80.17.1383. [DOI] [PubMed] [Google Scholar]
  7. Chambers T. C., McAvoy E. M., Jacobs J. W., Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990 May 5;265(13):7679–7686. [PubMed] [Google Scholar]
  8. Chin K. V., Chauhan S. S., Pastan I., Gottesman M. M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990 Aug;1(8):361–365. [PubMed] [Google Scholar]
  9. Chin K. V., Tanaka S., Darlington G., Pastan I., Gottesman M. M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem. 1990 Jan 5;265(1):221–226. [PubMed] [Google Scholar]
  10. Cho-Chung Y. S., Clair T., Tagliaferri P., Ally S., Katsaros D., Tortora G., Neckers L., Avery T. L., Crabtree G. W., Robins R. K. Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. Cancer Invest. 1989;7(2):161–177. doi: 10.3109/07357908909038282. [DOI] [PubMed] [Google Scholar]
  11. Cordon-Cardo C., O'Brien J. P., Boccia J., Casals D., Bertino J. R., Melamed M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990 Sep;38(9):1277–1287. doi: 10.1177/38.9.1974900. [DOI] [PubMed] [Google Scholar]
  12. Cornwell M. M., Smith D. E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem. 1993 Sep 15;268(26):19505–19511. [PubMed] [Google Scholar]
  13. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  15. Gros P., Croop J., Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell. 1986 Nov 7;47(3):371–380. doi: 10.1016/0092-8674(86)90594-5. [DOI] [PubMed] [Google Scholar]
  16. Guadagni F., Tortora G., Roselli M., Clair T., Cho-Chung Y. S., Schlom J., Greiner J. W. Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic AMP analogue: a comparison with interferon-gamma. Int J Cancer. 1991 May 30;48(3):413–422. doi: 10.1002/ijc.2910480319. [DOI] [PubMed] [Google Scholar]
  17. Hall J. L., Dudley L., Dobner P. R., Lewis S. A., Cowan N. J. Identification of two human beta-tubulin isotypes. Mol Cell Biol. 1983 May;3(5):854–862. doi: 10.1128/mcb.3.5.854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hamilton T. C., Winker M. A., Louie K. G., Batist G., Behrens B. C., Tsuruo T., Grotzinger K. R., McKoy W. M., Young R. C., Ozols R. F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 1985 Jul 15;34(14):2583–2586. doi: 10.1016/0006-2952(85)90551-9. [DOI] [PubMed] [Google Scholar]
  19. Herzog C. E., Trepel J. B., Mickley L. A., Bates S. E., Fojo A. T. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst. 1992 May 6;84(9):711–716. doi: 10.1093/jnci/84.9.711. [DOI] [PubMed] [Google Scholar]
  20. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  21. Hug V., Johnston D., Finders M., Hortobagyi G. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res. 1986 Jan;46(1):147–152. [PubMed] [Google Scholar]
  22. Kim S. H., Park J. I., Chung B. S., Kang C. D., Hidaka H. Inhibition of MDR1 gene expression by H-87, a selective inhibitor of cAMP-dependent protein kinase. Cancer Lett. 1993 Oct 15;74(1-2):37–41. doi: 10.1016/0304-3835(93)90041-7. [DOI] [PubMed] [Google Scholar]
  23. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 1991 Jul 25;19(14):3998–3998. doi: 10.1093/nar/19.14.3998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Langeveld C. H., Jongenelen C. A., Heimans J. J., Stoof J. C. Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3':5'-monophosphate. Cancer Res. 1992 Jul 15;52(14):3994–3999. [PubMed] [Google Scholar]
  25. Madden M. J., Morrow C. S., Nakagawa M., Goldsmith M. E., Fairchild C. R., Cowan K. H. Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem. 1993 Apr 15;268(11):8290–8297. [PubMed] [Google Scholar]
  26. Mickley L. A., Bates S. E., Richert N. D., Currier S., Tanaka S., Foss F., Rosen N., Fojo A. T. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem. 1989 Oct 25;264(30):18031–18040. [PubMed] [Google Scholar]
  27. Murphy L. D., Herzog C. E., Rudick J. B., Fojo A. T., Bates S. E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990 Nov 13;29(45):10351–10356. doi: 10.1021/bi00497a009. [DOI] [PubMed] [Google Scholar]
  28. Murphy L. D., Valverius E. M., Tsokos M., Mickley L. A., Rosen N., Bates S. E. Modulation of EGF receptor expression by differentiating agents in human colon carcinoma cell lines. Cancer Commun. 1990;2(10):345–355. doi: 10.3727/095535490820874092. [DOI] [PubMed] [Google Scholar]
  29. Okabe-Kado J., Hayashi M., Honma Y., Hozumi M., Tsuruo T. Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells. Cancer Res. 1991 May 15;51(10):2582–2586. [PubMed] [Google Scholar]
  30. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  31. Richert N. D., Aldwin L., Nitecki D., Gottesman M. M., Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry. 1988 Oct 4;27(20):7607–7613. doi: 10.1021/bi00420a006. [DOI] [PubMed] [Google Scholar]
  32. Ro J., Sahin A., Ro J. Y., Fritsche H., Hortobagyi G., Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol. 1990 Aug;21(8):787–791. doi: 10.1016/0046-8177(90)90046-8. [DOI] [PubMed] [Google Scholar]
  33. Rohlff C., Clair T., Cho-Chung Y. S. 8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem. 1993 Mar 15;268(8):5774–5782. [PubMed] [Google Scholar]
  34. Rudland P. S., Hughes C. M. Immunocytochemical identification of cell types in human mammary gland: variations in cellular markers are dependent on glandular topography and differentiation. J Histochem Cytochem. 1989 Jul;37(7):1087–1100. doi: 10.1177/37.7.2471725. [DOI] [PubMed] [Google Scholar]
  35. Saceda M., Lippman M. E., Chambon P., Lindsey R. L., Ponglikitmongkol M., Puente M., Martin M. B. Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol. 1988 Dec;2(12):1157–1162. doi: 10.1210/mend-2-12-1157. [DOI] [PubMed] [Google Scholar]
  36. Schecter R. L., Woo A., Duong M., Batist G. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res. 1991 Mar 1;51(5):1434–1442. [PubMed] [Google Scholar]
  37. Schneider J., Bak M., Efferth T., Kaufmann M., Mattern J., Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 1989 Dec;60(6):815–818. doi: 10.1038/bjc.1989.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  39. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  40. Takemura Y., Kobayashi H., Miyachi H., Hayashi K., Sekiguchi S., Ohnuma T. The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro. Cancer Chemother Pharmacol. 1991;27(6):417–422. doi: 10.1007/BF00685154. [DOI] [PubMed] [Google Scholar]
  41. Tanaka S., Currier S. J., Bruggemann E. P., Ueda K., Germann U. A., Pastan I., Gottesman M. M. Use of recombinant P-glycoprotein fragments to produce antibodies to the multidrug transporter. Biochem Biophys Res Commun. 1990 Jan 15;166(1):180–186. doi: 10.1016/0006-291x(90)91928-l. [DOI] [PubMed] [Google Scholar]
  42. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Thomas T. C., McNamee M. G. Purification of membrane proteins. Methods Enzymol. 1990;182:499–520. doi: 10.1016/0076-6879(90)82040-9. [DOI] [PubMed] [Google Scholar]
  44. Thorgeirsson S. S., Huber B. E., Sorrell S., Fojo A., Pastan I., Gottesman M. M. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science. 1987 May 29;236(4805):1120–1122. doi: 10.1126/science.3576227. [DOI] [PubMed] [Google Scholar]
  45. Tortora G., Clair T., Katsaros D., Ally S., Colamonici O., Neckers L. M., Tagliaferri P., Jahnsen T., Robins R. K., Cho-Chung Y. S. Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2849–2852. doi: 10.1073/pnas.86.8.2849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tortora G., Yokozaki H., Pepe S., Clair T., Cho-Chung Y. S. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):2011–2015. doi: 10.1073/pnas.88.5.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Ueda K., Clark D. P., Chen C. J., Roninson I. B., Gottesman M. M., Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987 Jan 15;262(2):505–508. [PubMed] [Google Scholar]
  48. Ueda K., Pastan I., Gottesman M. M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem. 1987 Dec 25;262(36):17432–17436. [PubMed] [Google Scholar]
  49. Van Lookeren Campagne M. M., Villalba Díaz F., Jastorff B., Kessin R. H. 8-Chloroadenosine 3',5'-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. Cancer Res. 1991 Mar 15;51(6):1600–1605. [PubMed] [Google Scholar]
  50. Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst. 1991 Jan 16;83(2):111–116. doi: 10.1093/jnci/83.2.111. [DOI] [PubMed] [Google Scholar]
  51. Vickers P. J., Dickson R. B., Shoemaker R., Cowan K. H. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol. 1988 Oct;2(10):886–892. doi: 10.1210/mend-2-10-886. [DOI] [PubMed] [Google Scholar]
  52. Wishart G. C., Plumb J. A., Going J. J., McNicol A. M., McArdle C. S., Tsuruo T., Kaye S. B. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer. 1990 Nov;62(5):758–761. doi: 10.1038/bjc.1990.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Yu L., Cohen D., Piekarz R. L., Horwitz S. B. Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdr1b gene. J Biol Chem. 1993 Apr 5;268(10):7520–7526. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES